Reanalysis of Popular Antidepressant Trial Uncovers Reporting Flaws

A reanalysis of a study found that fluoxetine alone showed no measurable benefit over placebo in treating adolescent depression after 12 weeks Researchers uncovered 11 additional suicide-related events that were hidden or misclassified, bringing the total to 21 serious incidents Statistical tactics and selective reporting made fluoxetine appear safer and more effective than it really was in clinical trials A different reanalysis mentioned that adverse events and many side effects were minimized or excluded from the original reports Improving gut health, getting regular exercise, undergoing therapy, and optimizing vitamin D are viable approaches for treating depression